Cardiovascular Therapeutic Drugs: Technologies and Global Markets

Report Summary

The global cardiovascular therapeutic drug market was worth $140.7 billion in 2009, and is expected to grow by a compound annual growth rate (CAGR) of 2.7% to $144.5 billion in 2010. This market will experience a sizable reduction in the early portion of the forecast period, and then slowly rise to reach $139.8 billion in 2015, a CAGR of -0.7%.

The hypertension segment recorded $64.9 billion in sales in 2009. By a large margin, hypertension is the largest segment within the cardiovascular market, driven by a large number of billion-dollar-plus therapies. The market is expected to grow to $65.3 billion in 2010 and experience a reduction through 2015 to $53.7 billion, a compound annual growth rate (CAGR) of -3.9%.

Treatment for hyperlipidemia recorded sales of more than $33 billion in 2009. Large therapeutic drugs including Lipitor and Crestor comprise a high concentration of this segment. Driven by patent expirations for Lipitor, and other drugs within this segment, the segment will shrink to about $26 billion by 2015, a CAGR of -4.3%. 

INTRODUCTION

STUDY GOALS AND OBJECTIVES

This study provides a comprehensive analysis of cardiovascular therapies on a global basis. Its aim is to provide a range of information, from detailed product analyses within disease subsegments to overall industry trends, in order to quantify and qualify the market for therapeutic drug products in the cardiovascular segment. Individual products are forecast on a global basis, as are overall segments. Forecasts and trends are developed from a cross-reference of data points, gleaned from proprietary industry sources, company publications, industry benchmarking, and other divergent data sources to arrive at a cogent and coordinated forecast.

REASONS FOR DOING THE STUDY

For companies with an effective strategy, market opportunity awaits. Importantly, the ability to develop an effective strategy begins with where opportunity exists and ends with how to effectively execute to capture profit from opportunity.

The cardiovascular therapeutic market is the largest of any drug sector. In addition, companies that hold patent rights to the largest drug classes have elected to exit the sector, opening the market up to the next tier of participants.

Market growth has been spurred by the introduction of differentiated therapies due to novel mechanism of action, such as P2Y12 inhibitors and Factor Xa inhibitors. In contrast to technical innovation, patent expiry is producing a severe headwind as evidenced by Lipitor and Plavix which are expected to drop $19 billion in one-year sales in 2015 from 2010.

This study investigates one of the most important market drivers: the introduction of combination therapies, which are expected to continue to contribute substantially to market growth through the forecast period. Combination therapies for hypertension are anticipated, as evidenced by Valturna (Novartis, Diovan and Tekturna) and Exforge (Novartis, Diovan and amlodipine).

This report analyzes emerging markets, by disease segment. Continued growth is expected in emerging geographies, driven by the growing middle class in emerging countries such as India, China, Brazil and Russia.

This report seeks to address the critically important topics of analyzing a changing market dynamic, emerging players and technologies, strategies for accessing emerging markets, and specific disease segments and geographies in order to allocate resources and make effective decisions.

SCOPE OF REPORT

Current and projected product forecasts during the forecast period (2010 to 2015) are discussed. As well, new products approved in 2009 and 2010 by the FDA, and those products expected to be approved within the forecast period are projected. 2010 is an estimated figure, except where actual results have been reported, due to the release timing of the report. For large markets segments such as hypertension, hyperlipidemia, and thrombosis, specific mechanisms of action are discussed in detail. For example, the trend of increased use of statins as a first-line therapy as compared to beta blockers and heparin therapies is analyzed. For each core segment within the overall market, leading products are analyzed for their differentiation by mechanism of action. The attempt to pursue and seek approval for PDE5 inhibitors is discussed in detail.

The report includes analysis of leading and emerging competitors in the current worldwide cardiovascular market. Profiles of manufacturers of leading products as well as biotechnology companies with novel products in development are analyzed to define their specific product strategies employed. This report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment. The competitive environment is examined with a special focus on how new products and technologies are influencing the current standard of care. Detailed profiles of current market leaders are discussed, as well as companies with innovative products poised to advance within the forecast period.

Market figures are based on revenues at the manufacturers’ level and are projected at 2010-dollar value. Inflation is not computed into the projection figures. Trends are assessed based on projected sales for existing products, new product introductions, expanded indications for existing products, and projected changes in the prevalence, diagnosis, and scripting rates for certain diseases.

Included in this report are forecasts by product, product category, and by company from 2009 through 2015. The study is arranged to offer an overview of the cardiovascular market accompanied by product, company, geography, and mechanism of action with forecasts broken down and covered by geographic region or country. Virtually the entire globe is covered to include prevalence data, for each disease sub segment.

Excluded from this report are over-the-counter (OTC) medications, and other consumables that do not require a physician’s prescription.

Sales figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change. Revenue figures do not account for variation in local currencies.

All market share data presented is on a global basis, unless specifically noted.

INTENDED AUDIENCE

This report is an invaluable tool for business planners, acquisitions specialists, licensing strategists, product managers, market research analysts, investors, investor consultants and anyone interested in the cardiovascular market, its products, its industry participants and its future.

The importance of identifying overall market trends, product opportunities, emerging geographies, M&A opportunities and insights that provide guidance for sales growth or defensive moves cannot be overstated for a variety of constituents, including:

• Established companies in the industry will benefit from the contents, including corporate strategy, sales and marketing, business development, and R&D.
• Emerging biotechnology players in the segment must understand specific opportunities for out-licensing, originating from the elements of differentiation of their therapeutic drug as compared to leading, competitive, and emerging therapies. As well, market forecasts can support investment, provided a thorough and detailed substantiation is provided for the market forecast, as is found in this study.
• Investment firms evaluating candidates for venture capital or hedged investments will gain insights as to the opportunity and risks that are being encountered in the industry, in a product and company specific analysis.
• Equity analysts are provided detailed forecasts for the next 5 years, substantiated by quantitative analysis that can support further analysis to product and company forecasts over the short and long run.

METHODOLOGY AND INFORMATION SOURCES

In-depth interviews were conducted with leading experts in the field who are executives in companies, industry analysts, and leading medical practitioners in the field.

Information to prepare this report was obtained from participating and emerging companies in the cardiovascular area; American Heart Association, the National Heart, Lung and Blood Institute and the National Heart, Lung, and Blood Institute; articles published in medical journals such as American Heart Journal, Circulation, Journal of Cardiovascular Pharmacology, Lancet, and others; the World Health Organization and other government agencies; literature searches; annual reports; 10Ks; and others. Population estimates are based on those reported by the International data base of the U.S. Census Bureau.

Current and historical revenue figures for individual products have been sourced from company disclosures that exist in the public domain or from government sources.

Table of Contents

CHAPTER ONE: INTRODUCTION

 

STUDY GOALS AND OBJECTIVES

REASONS FOR DOING THE STUDY

SCOPE OF REPORT

INTENDED AUDIENCE

METHODOLOGY AND INFORMATION SOURCES

RELATED REPORTS

BCC ONLINE SERVICES

DISCLAIMER

 

CHAPTER TWO: SUMMARY

 

SUMMARY TABLE GLOBAL CARDIOVASCULAR FORECAST BY DISEASE CLASS, THROUGH 2015 ($ MILLIONS)

 

SUMMARY FIGURE GLOBAL CARDIOVASCULAR FORECAST BY DISEASE CLASS, 2007-2015 ($ MILLIONS)

CHAPTER THREE: OVERVIEW

CURRENT STATE OF CARDIOVASCULAR DISEASE

FIGURE 1 LEADING CAUSES OF DEATH IN THE UNITED STATES; 2006 (DEATHS PER 100,000)

 

ESTABLISHED DRUG CLASSES IN CARDIOVASCULAR DISEASE

Statins

Angiotensin Receptor Blocker

Angiotensin Converting Enzyme (ACE) inhibitors

EMERGING DRUG CLASSES

P2Y12 Inhibitors and Antagonists

Factor Xa Inhibitors

Cholesterol-Ester Transfer Protein (CETP) Inhibitor

TABLE 1 CETP INHIBITORS IN ACTIVE DEVELOPMENT

 

KEY RECENT EVENTS IN THE CARDIOVASCULAR MARKET

PLAVIX METABOLIZER 2C19 TRIGGERS U.S. WARNING

VALTURNA IS FIRST TO RECEIVE U.S. APPROVAL AS COMBINATION THERAPY FOR HYPERTENSION

SUMMARY PIPELINE OF DRUGS IN DEVELOPMENT

TABLE 2 RECENTLY APPROVED DRUGS

 

TABLE 3 SUMMARY PIPELINE FORECAST

CHAPTER FOUR: INDUSTRY STRUCTURE AND COMPETITIVE ANALYSIS

INDUSTRY STRUCTURE

TABLE 4 CARDIOVASCULAR MARKET SEGMENTS, SIZE, GROWTH AND SHARE, THROUGH 2010 ($ MILLIONS)

 

MARKET CONCENTRATION AND PRICE SENSITIVITY

TABLE 5 COMPANY BY DISEASE CLASS, 2010 REVENUE ($ MILLIONS)

 

MARKET TRENDS

Overall Market Flat: Higher Mix of Generics Offset by Higher Volume

TABLE 6 PATENT EXPIRATION OF CARDIOVASCULAR DRUGS ($ MILLIONS)

 

Massive Patent Expiration is a Growth Opportunity for Generics

Market Expansion via Disease Prevention is the Future of Cardio Care

Atrial Fibrillation is a Large and Emerging Disease State

Combination Therapies are Synergistic Revenue Generators

TABLE 7 COMPANY BY DISEASE CLASS, 2015 REVENUE ($ MILLIONS)

 

TABLE 8 MARKET SHARE BY LEADING CARDIOVASCULAR PLAYERS ($ MILLIONS)

TABLE 9 LARGEST REVENUE GENERATING THERAPIES IN THE CARDIOVASCULAR SEGMENT, 2009 AND 2010 ($ MILLIONS)

CHAPTER FIVE: MARKETS BY DISEASE

SUMMARY OF MARKET DYNAMICS

TABLE 10 GLOBAL CARDIOVASCULAR FORECAST BY DISEASE CLASS, THROUGH 2015 ($ MILLIONS)

 

HYPERTENSION

PATHOPHYSIOLOGY AND PATHOGENESIS

Pathophysiology and Pathogenesis (Continued)

TABLE 11 HYPERTENSION STAGES AS MEASURED BY PRESSURE DIFFERENTIAL AT THE HEART (MMHG AND KILO-PASCAL)

 

TREATMENT AND MANAGEMENT

TABLE 12 CURRENT GLOBAL HYPERTENSION MARKET, 2007-2010 ($ MILLIONS)

 

Diovan/Co-Diovan

Micardis

Benicar

Norvasc

Cozaar/Hyzaar

TABLE 13 GLOBAL HYPERTENSION MARKET FORECAST, THROUGH 2015 ($ MILLIONS)

 

TABLE 14 FORECAST EPIDEMIOLOGY: HYPERTENSION

HYPERLIPIDEMIA

PATHOPHYSIOLOGY AND PATHOGENESIS

Genetic Factors in Hyperlipidemia

TABLE 15 GENERAL CLASSIFICATION OF HYPERLIPIDEMIA (TRIGLYCERIDE AND TOTAL CHOLESTEROL)

 

TABLE 16 FREDRICKSON CLASSIFICATION OF HYPERLIPIDEMIAS

TREATMENT AND MANAGEMENT

TABLE 17 CURRENT GLOBAL HYPERLIPIDEMIA MARKET, 2007-2010 ($ MILLIONS)

 

Lipitor

Crestor

Zetia

Vytorin

TABLE 18 GLOBAL HYPERLIPIDEMIA MARKET FORECAST, THROUGH 2015 ($ MILLIONS)

 

TABLE 19 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA

THROMBOSIS

PATHOPHYSIOLOGY AND PATHOGENESIS

TABLE 20 CURRENT GLOBAL THROMBOSIS MARKET, 2007-2010 ($ MILLIONS)

 

TREATMENT AND MANAGEMENT

Plavix

Lovenox

TABLE 21 GLOBAL THROMBOSIS MARKET FORECAST, THROUGH 2015 ($ MILLIONS)

 

CARDIAC FAILURE DISEASE

PATHOPHYSIOLOGY AND PATHOGENESIS

Stroke

TABLE 22 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015

 

Cardiac Arrhythmias

Angina Pectoris

Myocardial Infarction (MI)

Congestive Heart Failure (CHF)

Acute Coronary Syndrome (ACS)

TABLE 23 CURRENT GLOBAL CARDIAC FAILURE MARKET, 2007-2010 ($ MILLIONS)

 

TREATMENT AND MANAGEMENT

Vastarel

Other Drugs

TABLE 24 GLOBAL CARDIAC FAILURE MARKET FORECAST, THROUGH 2015 ($ MILLIONS)

 

OTHER CARDIOVASCULAR DISEASE

PATHOPHYSIOLOGY AND PATHOGENESIS

Pulmonary Hypertension

Peripheral Artery Disease (PAD)

TABLE 25 OTHER CARDIOVASCULAR DISEASE CURRENT GLOBAL MARKET ($ MILLIONS)

 

TREATMENT AND MANAGEMENT

Tracleer

Other Drugs

TABLE 26 OTHER CARDIOVASCULAR GLOBAL MARKET FORECAST, THROUGH 2015 ($ MILLIONS)

 

CHAPTER SIX: MARKETS BY DRUG CLASS

SUMMARY OF MARKET DYNAMICS

TABLE 27 CURRENT CARDIOVASCULAR MARKET BY DRUG CLASS, 2008-2010 ($ MILLIONS)

 

TABLE 28 CARDIOVASCULAR MARKET FORECAST BY DRUG CLASS, THROUGH 2015 ($ MILLIONS)

MONOTHERAPIES

STATINS

TABLE 29 STATIN CURRENT MARKET GROWTH AND SHARE, 2007-2010 ($ MILLIONS)

 

Genetic Influences to Statin Efficacy

TABLE 30 STATIN DRUG DOSING AND LDL REDUCTION CORRELATION

 

TABLE 31 STATIN MARKET FORECAST FOR HYPER-LIPIDEMIA, THROUGH 2015 ($ MILLIONS)

ANGIOTENSIN RECEPTOR BLOCKER (ARB)

TABLE 32 COMPARISON OF ARB PHARMACOKINETICS

 

TABLE 33 ARB CURRENT MARKET FOR HYPERTYENSION, GROWTH AND SHARE, 2007-2010 ($ MILLIONS)

Myocardial Infarction Risk Due to ARB Inhibition

ARB Impact on Alzheimer’s Disease Risk

TABLE 34 ARB MARKET FORECAST FOR HYPERTENSION, THROUGH 2015 ($ MILLIONS)

 

CALCIUM CHANNEL BLOCKERS (CCB)

TABLE 35 CCB CURRENT MARKET FOR HYPERTENSION, GROWTH AND SHARE, 2007-2010 ($ MILLIONS)

 

TABLE 36 CCB MARKET FORECAST FOR HYPERTENSION, THROUGH 2015 ($ MILLIONS)

LOW MOLECULAR WEIGHT HEPARINS (LMWH)

TABLE 37 LMWH CURRENT MARKET FOR THROMBOSIS, GROWTH AND SHARE, 2007-2010 ($ MILLIONS)

 

TABLE 38 LMWH MARKET FOR THROMBOSIS, FORECAST, THROUGH 2015 ($ MILLIONS)

ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS

TABLE 39 ACE INHIBITORS FOR HYPERTENSION, GOWTH AND SHARE, 2007-2010 ($ MILLIONS)

 

TABLE 40 ACE INHIBITOR MARKET FORECAST FOR HYPERTENSION, THROUGH 2015 ($ MILLIONS)

P2Y12 AND FACTOR XA INHIBITORS

Effient (Prasugrel): a Leading P2Y12 Antagonist

TABLE 41 P2Y12 CURRENT MARKET GROWTH AND SHARE, 2007-2010 ($ MILLIONS)

 

TABLE 42 PY12 MARKET FORECAST, THROUGH 2015 ($ MILLIONS)

TABLE 43 FACTOR XA CURRENT THROMBOIS MARKET GROWTH AND SHARE, 2007-2010 ($ MILLIONS)

TABLE 44 FACTOR XA MARKET FORECAST, THROUGH 2015 ($ MILLIONS)

COMBINATION DRUG CLASSES

CHAPTER SEVEN: MARKETS BY GEOGRAPHY

SUMMARY

TABLE 45 CURRENT MARKET SIZE BY GEOGRAPHY, 2009 AND 2010 ($ MILLIONS)

 

METHODOLOGY

TABLE 46 MARKET FORECAST BY GEOGRAPHY, THROUGH 2015 ($ MILLIONS)

 

UNITED STATES

TABLE 47 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (U.S.)

 

TABLE 48 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (U.S.)

TABLE 49 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (U.S.)

WESTERN EUROPE

TABLE 50 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (WESTERN EUROPE)

 

TABLE 51 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (WESTERN EUROPE)

TABLE 52 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (WESTERN EUROPE)

JAPAN

TABLE 53 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (JAPAN)

 

TABLE 54 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (JAPAN)

TABLE 55 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (JAPAN)

STRATEGIES TO ACCESS EMERGING MARKETS

EMERGING MARKETS FORECAST

BRAZIL

MARKET OVERVIEW

REGULATORY CONSIDERATIONS

PATENT CONSIDERATIONS

TABLE 56 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (BRAZIL)

 

TABLE 57 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (BRAZIL)

TABLE 58 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (BRAZIL)

CHINA

MARKET OVERVIEW

REGULATORY CONSIDERATIONS

PATENT CONSIDERATIONS

TABLE 59 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (CHINA)

 

TABLE 60 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (CHINA)

TABLE 61 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (CHINA)

INDIA

MARKET OVERVIEW

REGULATORY CONSIDERATIONS

PATENT CONSIDERATIONS

TABLE 62 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (INDIA)

 

TABLE 63 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (INDIA)

TABLE 64 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (INDIA)

RUSSIA

MARKET OVERVIEW

REGULATORY CONSIDERATIONS

PATENT CONSIDERATIONS

TABLE 65 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (RUSSIA)

 

TABLE 66 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (RUSSIA)

TABLE 67 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (RUSSIA)

SOUTH AMERICA

TABLE 68 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (SOUTH AMERICA)

 

TABLE 69 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (SOUTH AMERICA)

TABLE 70 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (SOUTH AMERICA)

CARRIBEAN

TABLE 71 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (CARRIBEAN)

 

TABLE 72 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (CARRIBEAN)

TABLE 73 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (CARRIBEAN)

NORTHERN EUROPE

TABLE 74 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (NORTHERN EUROPE)

 

TABLE 75 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (NORTHERN EUROPE)

TABLE 76 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (NORTHERN EUROPE)

CENTRAL AND EASTERN EUROPE

TABLE 77 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (CENTRAL & EASTERN EUROPE)

 

TABLE 78 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (CENTRAL & EASTERN EUROPE)

TABLE 79 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (CENTRAL & EASTERN EUROPE)

AUSTRALIA

TABLE 80 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (AUSTRALIA)

 

TABLE 81 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (AUSTRALIA)

TABLE 82 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (AUSTRALIA)

ASIA-OTHER

TABLE 83 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (ASIA-OTHER)

 

TABLE 84 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (ASIA-OTHER)

TABLE 85 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (ASIA-OTHER)

MIDDLE EAST

TABLE 86 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (MIDDLE EAST)

 

TABLE 87 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (MIDDLE EAST)

TABLE 88 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (MIDDLE EAST)

SOUTHERN AFRICA

TABLE 89 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (SOUTHERN AFRICA)

 

TABLE 90 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (SOUTHERN AFRICA)

TABLE 91 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (SOUTHERN AFRICA)

AFRICAN REGIONS EXCLUDED FROM EPIDEMIOLOGY FORECAST

CHAPTER EIGHT: PIPELINE ANALYSIS

TABLE 92 APPROVED PRODUCT FORECAST, 2010 AND 2015 ($ MILLIONS)

 

MARKET TRENDS ARISING FROM PIPELINE DEVELOPMENT

VALTURNA IS FIRST TO RECEIVE U.S. APPROVAL AS COMBINATION THERAPY FOR HYPERTENTION

ANTICOAGULANTS ENABLE NEW PRODUCT APPROVALS, IN PARTICULAR FACTOR XA

P2Y12 IS A PROVEN TARGET FOR MULTIPLE INDICATIONS; APPROVALS ARE EXPECTED

APOB-100 AS A NOVEL TREATMENT FOR HYPERLIPIDEMIA

INCREASED DRIVE TO ESTABLISH AND EXTEND HIGH HDL CHOLESTEROL LEVELS

2009 APPROVALS IN CARDIOVASCULAR THERAPY

MULTAQ (DRONEDARONE) - SANOFI-AVENTIS

TABLE 93 MULTAQ SNAPSHOT

 

XARELTO (RIVAROXABAN) - BAYER SCHERING/J&J

TABLE 94 XARELTO SNAPSHOT

 

EFFIENT/EFIENT (PRASUGREL) - ELI LILLY/DAIICHI SANKYO

TABLE 95 EFFIENT SNAPSHOT

 

RENDIX (DABIGATRAN) - BOEHRINGER INGELHEIM

TABLE 96 RENDIX SNAPSHOT

 

RECENTLY FILED/PRE-REGISTRATION COMPOUNDS

APIXABAN - BRISTOL-MYERS SQUIBB (BMS)/PFIZER

TABLE 97 APIXABAN SNAPSHOT

 

BRILINTA (TICAGRELOR/AZD6140) - ASTRAZENECA

TABLE 98 BRILINTA SNAPSHOT

 

CERTRIAD (ROSUVASTATIN/ FENOFIBRIC ACID) - ASTRAZENECA/ABBOTT

TABLE 99 CERTRIAD SNAPSHOT

 

PHASE II/III COMPOUNDS

LCZ696 - NOVARTIS

TABLE 100 LCZ696 SNAPSHOT

 

EDOXABAN (DU-176B) - DAIICHI SANKYO

TABLE 101 EDOXABAN (DU-176B) SNAPSHOT

 

SCH 530348 - MERCK

TABLE 102 SCH530348 SNAPSHOT

 

TYRISA/DARAPLADIB - GSK

TABLE 103 TYRISA SNAPSHOT

 

BETRIXABAN - PORTOLA/MERCK

TABLE 104 BETRIXABAN SNAPSHOT

 

PIPELINE ANALYSIS BY COMPANY

TABLE 105 PFIZER’S CARDIOVASCULAR PIPELINE

 

TABLE 106 SANOFI-AVENTIS’ CARDIOVASCULAR PIPELINE

TABLE 107 NOVARTIS’ CARDIOVASCULAR PIPELINE

TABLE 108 MERCK’S CARDIOVASCULAR PIPELINE

TABLE 109 BMS’ CARDIOVASCULAR PIPELINE

TABLE 110 ASTRA-ZENECA’S CARDIOVASCULAR PIPELINE

CHAPTER NINE: COMPANY PROFILES

SUMMARY

TABLE 111 COMPANY REVENUE AND MARKET SHARE ANALYSIS, 2007-2009 ($ MILLIONS)

 

TABLE 112 MARKET FORECAST BY COMPANY, THROUGH 2015 ($ MILLIONS)

ABBOTT LABORATORIES

Business Overview

Corporate Strategy

ACTELION LTD.

Business Overview

Leading Products

Corporate Strategy

ASTELLAS PHARMA, INC.

Business Overview

Leading Products

Corporate Strategy

ASTRAZENECA

Business Overview

Leading Products

Crestor

Atacand

Certriad

Corporate Strategy

BAYER AG

Business Overview

Leading Products

Adalat

BRISTOL-MYERS SQUIBB COMPANY

Business Overview

Leading Products

Plavix

Apixaban

Corporate Strategy

DAIICHI SANKYO, INC. (DAIICHI SANKYO GROUP)

Business Overview

Leading Products

Benicar

Effient

Corporate Strategy

ELI LILLY & CO.

Business Overview

Leading Products

FOREST LABORATORIES, INC.

Business Overview

Leading Products

Benicar

Corporate Strategy

GILEAD SCIENCES, INC.

Business Overview

Leading Products

Corporate Strategy

GLAXOSMITHKLINE (GSK)

Business Overview

Leading Products

Arixtra

Corporate Strategy

MERCK & CO., INC.

Business Overview

Leading Products

Vytorin

Zetia

Cozaar

Hyzaar

Zocor

Corporate Strategy

MYLAN, INC.

Business Overview

Corporate Strategy

NOVARTIS

Business Overview

Leading Products

Diovan

Co-Diovan

Exforge

Corporate Strategy

PFIZER, INC.

Business Overview

Leading Products

Lipitor

Norvasc

Revatio

Corporate Strategy

SANOFI AVENTIS

Business Overview

Leading Products

Plavix

Lovenox

Multaq

Corporate Strategy

TAKEDA PHARMACEUTICAL COMPANY LIMITED

Business Overview

Leading Products

Blopress

Atacand and Atacand Plus

Corporate Strategy

TEVA PHARMACEUTICAL INDUSTRIES LTD

Business Overview

Leading Products

Clopidogrel

Corporate Strategy

THE MEDICINES COMPANY, INC.

Website: www.themedicinescompany.com

Business Overview

Leading Products

Angiomax

Corporate Strategy

UNITED THERAPEUTICS CORPORATION

Business Overview

Leading Products

Remodulin

Corporate Strategy

LIST OF TABLES

SUMMARY TABLE GLOBAL CARDIOVASCULAR FORECAST BY

DISEASE CLASS, THROUGH 2015 ($ MILLIONS)

TABLE 1 CETP INHIBITORS IN ACTIVE DEVELOPMENT

TABLE 2 RECENTLY APPROVED DRUGS

TABLE 3 SUMMARY PIPELINE FORECAST

TABLE 4 CARDIOVASCULAR MARKET SEGMENTS, SIZE, GROWTH

AND SHARE, THROUGH 2010 ($ MILLIONS)

TABLE 5 COMPANY BY DISEASE CLASS, 2010 REVENUE ($ MILLIONS)

TABLE 6 PATENT EXPIRATION OF CARDIOVASCULAR DRUGS ($

MILLIONS)

TABLE 7 COMPANY BY DISEASE CLASS, 2015 REVENUE ($ MILLIONS)

TABLE 8 MARKET SHARE BY LEADING CARDIOVASCULAR PLAYERS

($ MILLIONS)

TABLE 9 LARGEST REVENUE GENERATING THERAPIES IN THE

CARDIOVASCULAR SEGMENT, 2009 AND 2010 ($ MILLIONS)

TABLE 10 GLOBAL CARDIOVASCULAR FORECAST BY DISEASE

CLASS, THROUGH 2015 ($ MILLIONS)

TABLE 11 HYPERTENSION STAGES AS MEASURED BY PRESSURE

DIFFERENTIAL AT THE HEART (MMHG AND KILO-PASCAL)

TABLE 12 CURRENT GLOBAL HYPERTENSION MARKET, 2007-2010 ($

MILLIONS)

TABLE 13 GLOBAL HYPERTENSION MARKET FORECAST, THROUGH

2015 ($ MILLIONS)

TABLE 14 FORECAST EPIDEMIOLOGY: HYPERTENSION

TABLE 15 GENERAL CLASSIFICATION OF HYPERLIPIDEMIA

(TRIGLYCERIDE AND TOTAL CHOLESTEROL)

TABLE 16 FREDRICKSON CLASSIFICATION OF HYPERLIPIDEMIAS

TABLE 17 CURRENT GLOBAL HYPERLIPIDEMIA MARKET, 2007-2010

($ MILLIONS)

TABLE 18 GLOBAL HYPERLIPIDEMIA MARKET FORECAST,

THROUGH 2015 ($ MILLIONS)

TABLE 19 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA

TABLE 20 CURRENT GLOBAL THROMBOSIS MARKET, 2007-2010 ($

MILLIONS)

TABLE 21 GLOBAL THROMBOSIS MARKET FORECAST, THROUGH

2015 ($ MILLIONS)

TABLE 22 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015

TABLE 23 CURRENT GLOBAL CARDIAC FAILURE MARKET, 2007-2010

($ MILLIONS)

TABLE 24 GLOBAL CARDIAC FAILURE MARKET FORECAST,

THROUGH 2015 ($ MILLIONS)

TABLE 25 OTHER CARDIOVASCULAR DISEASE CURRENT GLOBAL

MARKET ($ MILLIONS)

TABLE 26 OTHER CARDIOVASCULAR GLOBAL MARKET FORECAST,

THROUGH 2015 ($ MILLIONS)

TABLE 27 CURRENT CARDIOVASCULAR MARKET BY DRUG CLASS,

2008-2010 ($ MILLIONS)

TABLE 28 CARDIOVASCULAR MARKET FORECAST BY DRUG CLASS,

THROUGH 2015 ($ MILLIONS)

TABLE 29 STATIN CURRENT MARKET GROWTH AND SHARE, 2007-

2010 ($ MILLIONS)

TABLE 30 STATIN DRUG DOSING AND LDL REDUCTION

CORRELATION

TABLE 31 STATIN MARKET FORECAST FOR HYPER-LIPIDEMIA,

THROUGH 2015 ($ MILLIONS)

TABLE 32 COMPARISON OF ARB PHARMACOKINETICS

TABLE 33 ARB CURRENT MARKET FOR HYPERTYENSION, GROWTH

AND SHARE, 2007-2010 ($ MILLIONS)

TABLE 34 ARB MARKET FORECAST FOR HYPERTENSION, THROUGH

2015 ($ MILLIONS)

TABLE 35 CCB CURRENT MARKET FOR HYPERTENSION, GROWTH

AND SHARE, 2007-2010 ($ MILLIONS)

TABLE 36 CCB MARKET FORECAST FOR HYPERTENSION, THROUGH

2015 ($ MILLIONS)

TABLE 37 LMWH CURRENT MARKET FOR THROMBOSIS, GROWTH

AND SHARE, 2007-2010 ($ MILLIONS)

TABLE 38 LMWH MARKET FOR THROMBOSIS, FORECAST, THROUGH

2015 ($ MILLIONS)

TABLE 39 ACE INHIBITORS FOR HYPERTENSION, GOWTH AND

SHARE, 2007-2010 ($ MILLIONS)

TABLE 40 ACE INHIBITOR MARKET FORECAST FOR HYPERTENSION,

THROUGH 2015 ($ MILLIONS)

TABLE 41 P2Y12 CURRENT MARKET GROWTH AND SHARE, 2007-2010

($ MILLIONS)

TABLE 42 PY12 MARKET FORECAST, THROUGH 2015 ($ MILLIONS)

TABLE 43 FACTOR XA CURRENT THROMBOIS MARKET GROWTH

AND SHARE, 2007-2010 ($ MILLIONS)

TABLE 44 FACTOR XA MARKET FORECAST, THROUGH 2015 ($

MILLIONS)

TABLE 45 CURRENT MARKET SIZE BY GEOGRAPHY, 2009 AND 2010 ($

MILLIONS)

TABLE 46 MARKET FORECAST BY GEOGRAPHY, THROUGH 2015 ($

MILLIONS)

TABLE 47 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH

2015 (U.S.)

TABLE 48 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH

2015 (U.S.)

TABLE 49 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015

(U.S.)

TABLE 50 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH

2015 (WESTERN EUROPE)

TABLE 51 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH

2015 (WESTERN EUROPE)

TABLE 52 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015

(WESTERN EUROPE)

TABLE 53 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH

2015 (JAPAN)

TABLE 54 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH

2015 (JAPAN)

TABLE 55 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015

(JAPAN)

TABLE 56 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH

2015 (BRAZIL)

TABLE 57 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH

2015 (BRAZIL)

TABLE 58 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015

(BRAZIL)

TABLE 59 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH

2015 (CHINA)

TABLE 60 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH

2015 (CHINA)

TABLE 61 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015

(CHINA)

TABLE 62 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH

2015 (INDIA)

TABLE 63 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH

2015 (INDIA)

TABLE 64 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015

(INDIA)

TABLE 65 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH

2015 (RUSSIA)

TABLE 66 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH

2015 (RUSSIA)

TABLE 67 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015

(RUSSIA)

TABLE 68 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH

2015 (SOUTH AMERICA)

TABLE 69 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH

2015 (SOUTH AMERICA)

TABLE 70 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015

(SOUTH AMERICA)

TABLE 71 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH

2015 (CARRIBEAN)

TABLE 72 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH

2015 (CARRIBEAN)

TABLE 73 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015

(CARRIBEAN)

TABLE 74 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH

2015 (NORTHERN EUROPE)

TABLE 75 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH

2015 (NORTHERN EUROPE)

TABLE 76 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015

(NORTHERN EUROPE)

TABLE 77 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH

2015 (CENTRAL & EASTERN EUROPE)

TABLE 78 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH

2015 (CENTRAL & EASTERN EUROPE)

TABLE 79 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015

(CENTRAL & EASTERN EUROPE)

TABLE 80 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH

2015 (AUSTRALIA)

TABLE 81 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH

2015 (AUSTRALIA)

TABLE 82 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015

(AUSTRALIA)

TABLE 83 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH

2015 (ASIA-OTHER)

TABLE 84 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH

2015 (ASIA-OTHER)

TABLE 85 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015

(ASIA-OTHER)

TABLE 86 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH

2015 (MIDDLE EAST)

TABLE 87 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH

2015 (MIDDLE EAST)

TABLE 88 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015

(MIDDLE EAST)

TABLE 89 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH

2015 (SOUTHERN AFRICA)

TABLE 90 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH

2015 (SOUTHERN AFRICA)

TABLE 91 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015

(SOUTHERN AFRICA)

TABLE 92 APPROVED PRODUCT FORECAST, 2010 AND 2015 ($

MILLIONS)

TABLE 93 MULTAQ SNAPSHOT

TABLE 94 XARELTO SNAPSHOT

TABLE 95 EFFIENT SNAPSHOT

TABLE 96 RENDIX SNAPSHOT

TABLE 97 APIXABAN SNAPSHOT

TABLE 98 BRILINTA SNAPSHOT

TABLE 99 CERTRIAD SNAPSHOT

TABLE 100 LCZ696 SNAPSHOT

TABLE 101 EDOXABAN (DU-176B) SNAPSHOT

TABLE 102 SCH530348 SNAPSHOT

TABLE 103 TYRISA SNAPSHOT

TABLE 104 BETRIXABAN SNAPSHOT

TABLE 105 PFIZER’S CARDIOVASCULAR PIPELINE

TABLE 106 SANOFI-AVENTIS’ CARDIOVASCULAR PIPELINE

TABLE 107 NOVARTIS’ CARDIOVASCULAR PIPELINE

TABLE 108 MERCK’S CARDIOVASCULAR PIPELINE

TABLE 109 BMS’ CARDIOVASCULAR PIPELINE

TABLE 110 ASTRA-ZENECA’S CARDIOVASCULAR PIPELINE

TABLE 111 COMPANY REVENUE AND MARKET SHARE ANALYSIS,

2007-2009 ($ MILLIONS)

TABLE 112 MARKET FORECAST BY COMPANY, THROUGH 2015 ($

MILLIONS)

LIST OF FIGURES

SUMMARY FIGURE GLOBAL CARDIOVASCULAR FORECAST BY

DISEASE CLASS, 2007-2015 ($ MILLIONS)

FIGURE 1 LEADING CAUSES OF DEATH IN THE UNITED STATES;

2006 (DEATHS PER 100,000)